In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells

Tsang Pai Liu, Yi Han Hong, Pei Ming Yang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although sorafenib has been approved for treating hepatocellular carcinoma (HCC), clinical results are not satisfactory. Polypharmacology (one drug with multiple molecular targets) is viewed as an attractive strategy for identifying novel mechanisms of a drug and then rationally designing more-effective next-generation therapeutic agents. In this study, a polypharmacological study of sorafenib was performed by mining the next-generation Connectivity Map (CMap) database, CLUE (https://clue.io/). We found that sorafenib may act as a histone deacetylase (HDAC) inhibitor based on similar gene expression profiles. In vitro experimental analyses demonstrated that sorafenib indirectly inhibited HDAC activity in both sorafenib-sensitive and -resistant HCC cells. A cancer genomics analysis using the cBioPortal online tool showed the frequent upregulation of HDAC mRNAs. Furthermore, HCC patients with higher expressions of HDAC1 and HDAC2 had worse overall survival. Taken together, our study suggests that inhibition of HDAC by sorafenib may provide clinical benefits against HCC, and enhancement of HDAC-inhibitory activity of sorafenib may improve its therapeutic efficacy. In addition, our study also provides a novel strategy to study polypharmacology.

Original languageEnglish
Pages (from-to)86168-86180
Number of pages13
JournalOncotarget
Volume8
Issue number49
DOIs
Publication statusPublished - Oct 17 2017

Fingerprint

Histone Deacetylases
Computer Simulation
Hepatocellular Carcinoma
Polypharmacology
Histone Deacetylase Inhibitors
Genomics
In Vitro Techniques
sorafenib
Transcriptome
Pharmaceutical Preparations
Up-Regulation
Databases
Messenger RNA
Survival
Therapeutics
Neoplasms

Keywords

  • Connectivity map (CMap)
  • Hepatocellular carcinoma (HCC)
  • Histone deacetylase (HDAC)
  • Polypharmacology
  • Sorafenib

ASJC Scopus subject areas

  • Oncology

Cite this

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells. / Liu, Tsang Pai; Hong, Yi Han; Yang, Pei Ming.

In: Oncotarget, Vol. 8, No. 49, 17.10.2017, p. 86168-86180.

Research output: Contribution to journalArticle

@article{e5f408934e86471aa10688e48fb3a00e,
title = "In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells",
abstract = "Although sorafenib has been approved for treating hepatocellular carcinoma (HCC), clinical results are not satisfactory. Polypharmacology (one drug with multiple molecular targets) is viewed as an attractive strategy for identifying novel mechanisms of a drug and then rationally designing more-effective next-generation therapeutic agents. In this study, a polypharmacological study of sorafenib was performed by mining the next-generation Connectivity Map (CMap) database, CLUE (https://clue.io/). We found that sorafenib may act as a histone deacetylase (HDAC) inhibitor based on similar gene expression profiles. In vitro experimental analyses demonstrated that sorafenib indirectly inhibited HDAC activity in both sorafenib-sensitive and -resistant HCC cells. A cancer genomics analysis using the cBioPortal online tool showed the frequent upregulation of HDAC mRNAs. Furthermore, HCC patients with higher expressions of HDAC1 and HDAC2 had worse overall survival. Taken together, our study suggests that inhibition of HDAC by sorafenib may provide clinical benefits against HCC, and enhancement of HDAC-inhibitory activity of sorafenib may improve its therapeutic efficacy. In addition, our study also provides a novel strategy to study polypharmacology.",
keywords = "Connectivity map (CMap), Hepatocellular carcinoma (HCC), Histone deacetylase (HDAC), Polypharmacology, Sorafenib",
author = "Liu, {Tsang Pai} and Hong, {Yi Han} and Yang, {Pei Ming}",
year = "2017",
month = "10",
day = "17",
doi = "10.18632/oncotarget.21030",
language = "English",
volume = "8",
pages = "86168--86180",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "49",

}

TY - JOUR

T1 - In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells

AU - Liu, Tsang Pai

AU - Hong, Yi Han

AU - Yang, Pei Ming

PY - 2017/10/17

Y1 - 2017/10/17

N2 - Although sorafenib has been approved for treating hepatocellular carcinoma (HCC), clinical results are not satisfactory. Polypharmacology (one drug with multiple molecular targets) is viewed as an attractive strategy for identifying novel mechanisms of a drug and then rationally designing more-effective next-generation therapeutic agents. In this study, a polypharmacological study of sorafenib was performed by mining the next-generation Connectivity Map (CMap) database, CLUE (https://clue.io/). We found that sorafenib may act as a histone deacetylase (HDAC) inhibitor based on similar gene expression profiles. In vitro experimental analyses demonstrated that sorafenib indirectly inhibited HDAC activity in both sorafenib-sensitive and -resistant HCC cells. A cancer genomics analysis using the cBioPortal online tool showed the frequent upregulation of HDAC mRNAs. Furthermore, HCC patients with higher expressions of HDAC1 and HDAC2 had worse overall survival. Taken together, our study suggests that inhibition of HDAC by sorafenib may provide clinical benefits against HCC, and enhancement of HDAC-inhibitory activity of sorafenib may improve its therapeutic efficacy. In addition, our study also provides a novel strategy to study polypharmacology.

AB - Although sorafenib has been approved for treating hepatocellular carcinoma (HCC), clinical results are not satisfactory. Polypharmacology (one drug with multiple molecular targets) is viewed as an attractive strategy for identifying novel mechanisms of a drug and then rationally designing more-effective next-generation therapeutic agents. In this study, a polypharmacological study of sorafenib was performed by mining the next-generation Connectivity Map (CMap) database, CLUE (https://clue.io/). We found that sorafenib may act as a histone deacetylase (HDAC) inhibitor based on similar gene expression profiles. In vitro experimental analyses demonstrated that sorafenib indirectly inhibited HDAC activity in both sorafenib-sensitive and -resistant HCC cells. A cancer genomics analysis using the cBioPortal online tool showed the frequent upregulation of HDAC mRNAs. Furthermore, HCC patients with higher expressions of HDAC1 and HDAC2 had worse overall survival. Taken together, our study suggests that inhibition of HDAC by sorafenib may provide clinical benefits against HCC, and enhancement of HDAC-inhibitory activity of sorafenib may improve its therapeutic efficacy. In addition, our study also provides a novel strategy to study polypharmacology.

KW - Connectivity map (CMap)

KW - Hepatocellular carcinoma (HCC)

KW - Histone deacetylase (HDAC)

KW - Polypharmacology

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85031498902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031498902&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21030

DO - 10.18632/oncotarget.21030

M3 - Article

VL - 8

SP - 86168

EP - 86180

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 49

ER -